Compositions and methods for protein detection

ABSTRACT

The invention relates generally to immunoassays, and more particularly to monoclonal antibodies and immunoassays for the differential detection and quantitation of a wild-type crystal protein, such as a wild-type-Cry1Ab, from Bacillus thuringiensis and hybrid crystal proteins, which comprise all or a significant portion of the wild-type Cry protein in complex biological samples comprising both the wild-type Cry protein and one or more of the hybrid Cry proteins.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of co-pending U.S. application Ser. No.15/755,721, filed Feb. 27, 2018, which is a 35 U.S.C. § 371 NationalStage application of PCT Application No. PCT/US16/48580, filed Aug. 25,2016, and published as WO2017/044310 on Mar. 16, 2017, which claims thebenefit of U.S. Provisional Application No. 62/215,982, filed Sep. 9,2015, all of which are incorporated by reference herein in theirentirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The official copy of the sequence listing is submitted electronicallyvia EFS-Web as an ASCII formatted sequence listing with a file named“80859-US-REG-ORG-P-1_SeqList_ST25.txt”, originally created on Sep. 8,2015, and having a size of 48 kilobytes and is filed concurrently withthe specification. The sequence listing contained in this ASCIIformatted document is part of the specification and is hereinincorporated by reference in its entirety.

FIELD OF THE INVENTION

The invention relates generally to immunoassays, and more particularlyto monoclonal antibodies and immunoassays for the differential detectionand quantitation of wild-type crystal proteins from Bacillusthuringiensis and hybrid crystal proteins in complex biological samples.

BACKGROUND

Bacillus thuringiensis is a ubiquitous gram-positive, spore-formingbacterium that forms a crystalline protein inclusion during thestationary phase of its growth cycle. The crystal proteins (Cryproteins) are toxic to a number of plant pests, including many insectsin the orders Lepidoptera and Coleoptera. Prior to 1990, the major Cryprotein classes were defined by their spectrum of activity with the Cry1proteins active against Lepidoptera (moths and butterflies), Cry2proteins active against both Lepidoptera and Diptera (flies andmosquitoes), Cry3 proteins active against Coleoptera (beetles) and Cry4proteins active against Diptera (Hofte and Whitely, 1989, Microbiol.Rev. 53:242 255). Subsequent to the Hofte and Whitely nomenclaturescheme, a different nomenclature was developed which systematicallyclassifies the Cry proteins based on amino acid sequence homology ratherthan insect target specificities (Crickmore et al. 1998, Microbiol. Mol.Biol. Rev. 62:807 813).

Most Cry proteins active against lepidopteran or coleopteran insects areformed in the crystalline matrix as 130-140 kDa or 60-70 kDa protoxins,respectively. In lepidopteran insects, the alkaline pH of the gutsolubilizes the crystal and then gut proteases process the 130-140 kDaprotoxin to toxic proteins of approximately 60-70 kDa. In coleopteraninsects, the 60-70 kDa protoxins are processed to 55-67 kDa toxins.Examples of lepidopteran-active Cry proteins include Cry1A, Cry1B,Cry1C, Cry1D, Cry1E, Cry1F and Cry9. Examples of coleopteran-active Cryproteins include, Cry3A, Cry3B, Cry3C, Cry8, the binary Cry23-Cry37 andthe binary Cry34-Cry35. Processing of the Cry protein protoxin to atoxin has been reported to proceed by removal of both N- and C-terminalamino acids with the exact location of processing being dependent on thespecific Cry protein and the specific insect gut fluids involved(Ogiwara et al., 1992. J. Invert. Pathol. 60:121-126). The proteolyticactivation of a Cry protoxin can play a significant role in determiningits specificity.

All or parts of certain wild-type Cry proteins have been used toengineer hybrid Cry proteins in attempts to create insecticidal proteinswith improved specific activity or broader spectrum of insecticidalactivity. Targeted engineering was made more possible by solving thethree dimensional structure of Cry3A by Li el al. (1991, Nature353:815-821). Based on this work, it has been determined that Cryproteins in general have three structural domains: the N-terminal domainI, from residues 1-290, consists of 7 alpha helices, domain II, fromresidues 291-500, contains three beta-sheets and the C-terminal domainIII, from residues 501-644, is a beta-sandwich. Based on this structure,a hypothesis has been formulated regarding the structure/functionrelationship of the Cry proteins. It is generally thought that domain Iis primarily responsible for pore formation in the insect gut membrane(Gazit and Shai, 1993, Appl. Environ. Microbiol. 57:2816 2820), domainII is primarily responsible for interaction with the gut receptor (Ge elal., 1991, J. Biol. Chem. 32:3429 3436) and that domain III is mostlikely involved with protein stability (Li et al. 1991, supra) as wellas having a regulatory impact on ion channel activity (Chen et al.,1993, PNAS 90:9041 9045).

Many successful attempts to create hybrid Cry proteins have beendisclosed in the literature. For example, the silk moth (Bombyx mori)specificity domain from a Cry1Aa protein was moved to a Cry1Ac protein,thus imparting a new insecticidal activity to the resultingCry1Aa-Cry1Ac chimeric protein (Ge et al. 1989, PNAS 86: 4037 4041).Thompson et al. 1996 and 1997 (U.S. Pat. Nos. 5,527,883 and 5,593,881)replaced the protoxin tail region of a wild-type Cry1F protein and Cry1Cprotein with the protoxin tail region of a Cry1Ab protein to make aCry1F-Cry1Ab hybrid Cry protein and a Cry1C-Cry1Ab hybrid Cry protein,both having improved expression in certain expression host cells. Boschet al. 1998 (U.S. Pat. No. 5,736,131), created new lepidopteran-activeproteins by substituting domain III of a Cry1Ea protein and a Cry1Abprotein with domain III of Cry1Ca protein thus producing a Cry1E-Cry1Chybrid Cry protein called G27 and a Cry1Ab-Cry1C hybrid Cry proteincalled H04, both of which have a broader spectrum of lepidopteranactivity than the wild-type Cry protein parent molecules. Malvar et al.2001 (U.S. Pat. No. 6,242,241) combined domain I of a Cry1Ac proteinwith domains II and III and the protoxin tail of a Cry1F protein tocreate a Cry1Ac-Cry1F hybrid Cry protein with broader insecticidalactivity than the parental wild-type Cry proteins. Bogdanova et al. 2011(U.S. Pat. No. 8,034,997) combined domains I and II of a Cry1Ab proteinwith domain III of a Cry1Fa protein and added a Cry1Ac protein protoxintail to create a new lepidopteran-active hybrid Cry protein calledCry1A.105. And, Hart et al. 2012 (U.S. Pat. No. 8,309,516) combineddomains I and II of a modified Cry3A protein with domain III of a Cry1Abprotein and added a portion of a Cry1Ab protein protoxin tail to createa coleopteran-active hybrid Cry protein called FR8a (also calledeCry3.1Ab). Most of the reported hybrid Cry proteins to date have usedall or parts of the same classes of wild-type Cry proteins, such asCry1Aa, Cry1Ab, Cry1Ac, Cry1C, Cry1F and Cry3A.

Several wild-type Cry proteins, for example Cry1Ab, Cry1Ac, Cry1C,Cry1F, Cry2A, Cry2Ba, Cry3A, Cry3B, Cry9C, and Cry34-Cry35 have beenexpressed in transgenic crop plants, including corn, cotton, rice andsoybean, some of which have been exploited commercially to controlcertain lepidopteran and coleopteran insect pests since as early as1996. More recently, transgenic crop products containing hybrid Cryproteins, for example Cry1A.105 (Cry1Ab-Cry1F-Cry1Ac) and eCry3.1Ab(mCry3A-Cry3A-Cry1Ab), have been introduced commercially.

Immunoassay is the current preferred method in the agricultural industryfor detection and quantification of Cry proteins introduced throughgenetic modification of plants. The crucial component of an immunoassayis an antibody with specificity for the target molecule (antigen).Immunoassays can be highly specific and samples often need only a simplepreparation before being analyzed. Moreover, immunoassays can be usedqualitatively or quantitatively over a wide range of concentrations.Typically, immunoassays require separate tests for each Cry protein ofinterest.

The antibodies can be polyclonal, raised in animals, or monoclonal,produced by cell cultures. Commercially available polyclonal antiserumis often produced in rabbits, goats or sheep. Monoclonal antibodiesoffer some advantages over polyclonal antibodies because they expressuniform affinity and specificity against a single epitope or antigenicdeterminant and can be produced in vast quantities. Both polyclonal andmonoclonal antibodies may require further purification steps to enhancethe sensitivity and reduce backgrounds in assays.

Making a valid identification of a product containing a Cry protein orquantitating a Cry protein in a commercial product depends on theaccuracy of the immunoassay. Development of a successful immunoassaydepends on certain characteristics of the antigen used for developmentof the antibody, i.e. size, hydrophobicity and the tertiary structure ofthe antigen. The specificity of the antibodies must be checked carefullyto elucidate any cross-reactivity with similar substances, which mightcause false positive results. A current problem in the industry is thatmany of the antibodies in commercially available tests kits do notdifferentiate between various products or wild-type Cry proteins, makingdifferential product identification and quantitation difficult orimpossible.

With many current commercial transgenic crop products using one or moreof the same wild-type Cry proteins, for example Cry1Ab, Cry1F and Cry3,and with the introduction of crops expressing hybrid Cry proteins madeof whole or parts of the same wild-type Cry proteins that are already intransgenic crop products, there is a continuing need to develop new andimproved immunoassays to be able to distinguish a wild-type Cry proteinfrom a hybrid Cry protein containing all or portions of that samewild-type Cry protein when they are together in complex biologicalsamples, such as samples from transgenic plants.

SUMMARY

The present invention addresses the need for new and improvedimmunoassays by providing compositions useful in specific detection anddifferentiation of certain wild-type Cry proteins and engineered hybridCry proteins comprising all or part of the wild-type Cry protein aminoacid sequence in complex biological samples, including transgenic plantsamples. The invention also relates to methods, assays and kits tospecifically detect and differentiate wild-type Cry proteins fromengineered hybrid Cry proteins comprising all or part of the wild-typeCry protein amino acid sequence in biological samples comprising thewild-type Cry protein and the hybrid Cry protein.

According to one aspect, the invention provides a composition comprisinga first antibody and a second antibody that function together tospecifically detect or quantitate a Cry1Ab protein in an immunoassay ofa biological sample comprising the Cry1Ab protein and a hybrid Cryprotein having at least a contiguous 27% of the Cry1Ab protein's aminoacid sequence, wherein the first antibody and the second antibodyindividually are capable of binding to both the wild-type Cry1Ab proteinand the hybrid Cry protein.

According to another aspect, the invention also provides a pair ofpurified antibodies comprising a first antibody and a second antibodythat function together in an immunoassay to specifically detect orquantitate a Cry1Ab protein in a biological sample comprising the Cry1Abprotein and a hybrid Cry protein having at least a contiguous 27% of theCry1Ab protein's amino acid sequence, wherein the first antibody and thesecond antibody individually are capable of binding to both the Cry1Abprotein and the hybrid Cry protein.

According to yet another aspect of this invention, a diagnostic kit isprovided for detecting a Cry1Ab protein in a biological sample whichcomprises the Cry1Ab protein and a hybrid Cry protein having at least acontiguous 27% of the Cry1Ab protein's amino acid sequence, wherein thekit comprises a first antibody and a second antibody that functiontogether to specifically detect or quantitate the Cry1Ab protein andthat individually are capable of binding both the Cry1Ab protein and thehybrid Cry protein.

In certain embodiments of the above described aspects of the invention,the immunoassay is a enzyme-linked immunosorbent assay (ELISA),preferably a sandwich ELISA. In other embodiments of these aspects ofthe invention, the first antibody is the coating antibody and the secondantibody is the detecting antibody. In still other embodiments, thefirst and the second antibodies are monoclonal. In yet otherembodiments, the first or coating antibody is the monoclonal antibody87AB1.1, which is available from Romer Labs, Inc (Union, Mo.). In stillother embodiments, the second or detecting antibody is the monoclonalantibody H04MAb70 produced by the hybridoma cell line H04MAb70 depositedas ATCC Accession No. PTA-122984. In yet other embodiments, the coatingantibody is 87AB1.1 and the detecting antibody is H04MAb70.

In other embodiments of the above described aspects of the invention,the Cry1Ab protein comprises an amino acid sequence represented by SEQID NO:1, SEQ ID NO:2 or SEQ ID N:6. In other embodiments, the hybrid Cryprotein is eCry3.1Ab, the amino acid sequence of which is set forth inSEQ ID NO:3, H04, the amino acid sequence of which is set forth in SEQID NO:4 or Cry1A.105, the amino acid sequence of which is set forth inSEQ ID NO:5.

In other embodiments of the above described aspects of the invention,the biological sample is a transgenic plant sample. In otherembodiments, the transgenic plant is a transgenic corn plant comprisinga transgenic event selected from the group consisting of event Bt11,which comprises the Cry1Ab protein of SEQ ID NO:1, event 5307, whichcomprises the eCry3.1Ab hybrid Cry protein of SEQ ID NO:3, eventMON89034, which comprises the Cry1A.105 hybrid Cry protein of SEQ IDNO:5 and event MON810, which comprises the Cry1Ab protein of SEQ IDNO:6.

According to another aspect of the invention, there is provided ahybridoma cell line, designated H04MAb70, deposited as ATCC AccessionNo. PTA-122984, and a hybridoma cell line designated MAb58, deposited asATCC Accession No. PTA-122985. In certain embodiments of this aspect ofthe invention, there is provided a monoclonal antibody designatedH04MAb70 produced by the H04MAb hybridoma cell line that binds to both awild-type Cry1Ab protein and a hybrid Cry protein. In certain otherembodiments of this aspect of the invention, there is provided amonoclonal antibody designated MAb58 produced by the hybridoma cell lineMAb58 that binds to a hybrid Cry protein.

According to another aspect of the invention there is providedimmunoassay methods to specifically detect or quantitate a Cry1Abprotein in a biological sample comprising the Cry1Ab protein and ahybrid Cry protein having at least a contiguous 27% of the Cry1Abprotein's amino acid sequence. Such methods comprise (a) obtaining abiological sample comprising the Cry1Ab protein and the hybrid Cryprotein; and (b) performing an immunoassay on the biological sample,wherein the immunoassay comprises use of a first antibody and a secondantibody that individually are capable of binding to the Cry1Ab proteinand the hybrid Cry protein but that function together in the immunoassayto specifically detect or quantitate the Cry1Ab protein and not thehybrid Cry protein, resulting in the specific detection or quantitationof the Cry1Ab protein.

In some embodiments of this aspect, the immunoassay is an enzyme-linkedimmunosorbent assay (ELISA). In other embodiments, the first antibody isa coating antibody and the second antibody is a detecting antibody. Infurther embodiments, the coating antibody and the detecting antibody aremonoclonal. In still other embodiments, the coating antibody is themonoclonal antibody 87AB1.1 available from Romer Labs, Inc. (Union,Mo.). In yet other embodiments, the detecting antibody is the monoclonalantibody H04MAb70 produced by the hybridoma cell line deposited as ATCCAccession No. PTA-122984. In other embodiments, the coating antibody is87AB1.1 and the detecting antibody is H04MAb70.

In some embodiments of this aspect of the invention, the Cry1Ab proteincomprises an amino acid sequence selected from the group consisting ofSEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:6. In other embodiments, thehybrid Cry protein is selected from the group consisting of eCry3.1Ab(SEQ ID NO:3), Cry1A.105 (SEQ ID NO:4) and H04 (SEQ ID NO:5). In stillother embodiments, the Cry1Ab protein comprises the amino acid sequenceof SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:6 and the hybrid Cry proteinis eCry3.1Ab (SEQ ID NO:3) or Cry1A.105 (SEQ ID NO:4) or H04 (SEQ IDNO:5).

In some embodiments of this aspect of the invention, the biologicalsample tested in the immunoassay is a transgenic plant sample. In otherembodiments, the transgenic plant sample is from a transgenic cornplant. In other embodiments, the transgenic corn plant comprises atransgenic corn event selected from the group consisting of event Bt11,event 5307, event MON89034 and event MON810. In still other embodiments,the transgenic corn plant comprises event Bt11, event 5307 and eventMON89034. In yet further embodiments, the biological sample comprises aCry1Ab protein from event Bt11 and an eCry3.1Ab hybrid Cry protein fromevent 5307 and optionally a Cry1A.105 hybrid Cry protein from eventMON89034. In still further embodiments, the biological sample comprisesa Cry1Ab protein from event MON810 and a Cry1A.105 hybrid Cry proteinfrom event MON89034.

In another aspect of the invention there is provided immunoassay methodsfor detecting or quantitating both a Cry1Ab protein and a hybrid Cryprotein having at least a contiguous 27% of a Cry1Ab protein's aminoacid sequence in a biological sample comprising the hybrid Cry proteinand the Cry1Ab protein. Such immunoassay methods comprise: (a) obtaininga biological sample comprising the hybrid Cry protein and the Cry1Abprotein; (b) contacting the biological sample with a first antibodyunder conditions effective to allow the formation of a Cry1Ab-firstantibody complex but not a hybrid Cry protein-first antibody complex,resulting in a biological sample depleted of the Cry1Ab protein; (c)removing the Cry1Ab-depleted biological sample from contact with thefirst antibody; (d) contacting the Cry1Ab-depleted biological samplewith a second antibody under conditions effective to allow the formationof a hybrid Cry protein-second antibody complex; and (e) detecting orquantitating the hybrid Cry protein in the hybrid Cry protein-secondantibody complex.

In some embodiments of this aspect, the immunoassay is an enzyme-linkedimmunosorbent assay, wherein the solid surface is a well in a microtiterdish. In other embodiments, the hybrid Cry protein is eCry3.1Ab (SEQ IDNO:3) or Cry1A.105 (SEQ ID NO:4). In other embodiments, the firstantibody is 87AB1.1 which is available from Romer Labs, Inc. (Union,Mo.). In other embodiments, the second antibody is the monoclonalantibody MAb58 produced by the hybridoma cell line deposited as ATCCAccession No. PTA-122985. In yet other embodiments of this aspect, thedetecting of step (d) is carried out using a composition comprising amonoclonal antibody capable of binding to the Cry1Ab protein and thehybrid Cry protein. In still further embodiments, the monoclonalantibody is H04MAb70. In yet other embodiments of this aspect, thedetecting step (e) is carried out using a composition comprising amonoclonal antibody or a polyclonal antibody capable of binding to thehybrid Cry protein and the Cry1Ab protein. In further embodiments, themonoclonal antibody is H04MAb70 or the polyclonal antibody is PAb713available from Romer Labs, Inc. (Union, Mo.).

According to yet another aspect of the invention there is providedimmunoassay methods to detect or quantitate a hybrid Cry protein havingat least a contiguous 27% of a Cry1Ab protein's amino acid sequence in abiological sample comprising the hybrid Cry protein and the Cry1Abprotein. Such methods comprise: (a) obtaining a biological samplecomprising the hybrid Cry protein and the Cry1Ab protein; (b) contactingthe biological sample with a 87AB1.1 antibody under conditions effectiveto allow the formation of a Cry1Ab-87AB1.1 complex but not a hybrid Cryprotein-87AB1.1 complex, resulting in a biological sample depleted ofthe Cry1Ab protein; (c) removing the Cry1Ab-depleted biological samplefrom contact with the 87AB1.1 antibody; (d) contacting theCry1Ab-depleted biological sample with a second antibody underconditions effective to allow the formation of a hybrid Cryprotein-second antibody complex; and (e) detecting or quantitating thehybrid Cry protein in the hybrid Cry protein-second antibody complex.

In some embodiments of this aspect, the hybrid Cry protein is eCry3.1Ab(SEQ ID NO:3) or Cry1A.105 (SEQ ID NO:4).

In other embodiments, the biological sample is from a transgenic plant.In some other embodiments, the transgenic plant is a transgenic cornplant. In still other embodiments, the transgenic corn plant comprises atransgenic corn event selected from the group consisting of event Bt11,event 5307, event MON89034 and event MON810. In yet other embodiments,the transgenic corn plant comprises the transgenic corn event Bt11,event 5307 and event MON89034. In other embodiments, the transgenic cornplant comprises the transgenic event MON810 and the transgenic eventMON89034. In other embodiments, the biological sample comprises a Cry1Abprotein from event Bt11 and an eCry3.1Ab hybrid Cry protein from event5307 and optionally, a Cry1A.105 hybrid Cry protein from event MON89034.In still further embodiments, the biological sample comprises a Cry1Abprotein from event MON810 and a Cry1A.105 hybrid Cry protein from eventMON89034.

Various objects, features, aspects, and advantages of the presentinvention will become more apparent from the following detaileddescription of preferred embodiments of the invention, along with theaccompanying drawings and sequence listing.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a graphic of the structure of wild-type Cry1Ab proteins andhybrid Cry proteins having at least a contiguous 27% of the Cry1Abprotein's amino acid sequence showing the relationship of the Cry1Abportions of the hybrid Cry proteins and the wild-type Cry1Ab proteins.Proteins used to make antibodies of the invention are indicated as wellas proteins in commercial transgenic corn events.

FIG. 2 is an amino acid sequence alignment between wild-type Cry1Ab andan eCry3.1Ab hybrid Cry protein. The amino acids in eCry3.1Ab, aminoacids 480-653, that are a contiguous 27% of the Cry1Ab protein areunderlined.

FIG. 3 is an amino acid alignment between a wild-type Cry1Ab and aCry1A.105 hybrid Cry protein. The amino acids in Cry1A.105, amino acids1-467, that are a contiguous 40% of the Cry1Ab protein are underlined.

FIG. 4 is an amino acid alignment between a wild-type Cry1Ab and a H04hybrid Cry protein. The amino acids in H04, amino acids 1-460 and832-1188, that are a contiguous 30% and 39%, respectively, of the Cry1Abprotein are underlined. The H04 protein comprises a total of 69% ofwild-type Cry1Ab amino acids.

BRIEF DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 is an amino acid sequence of a wild-type Cry1Ab proteinexpressed in the transgenic corn event B tn.

SEQ ID NO:2 is an amino acid sequence of a wild-type Cry1Ab protein usedto make the MAb58 monoclonal antibody.

SEQ ID NO:3 is an amino acid sequence of a eCry3.1Ab hybrid Cry proteinexpressed in the transgenic corn event 5307.

SEQ ID NO:4 is an amino acid sequence of a Cry1A.105 hybrid Cry proteinexpressed in the transgenic corn event MON89034.

SEQ ID NO:5 is an amino acid sequence of a H04 hybrid Cry used to makethe H04MAb70 monoclonal antibody.

SEQ ID NO:6 is an amino acid sequence of a wild-type Cry1Ab proteinexpressed in the transgenic corn event MON810.

DEPOSITS

Hybridoma cell line H04MAb70 and Hybridoma cell line MAb58 weredeposited with the American Type Culture Collection, 10801 UniversityBlvd., Manassas, Va., on Mar. 30, 2016 and have the following accessionnumbers: HO4Mab70: PTA-122984 and Mab58: PTA-122985. Both deposits weremade under the terms of the Budapest Treaty on the InternationalRecognition of the Deposit of Microorganisms for the Purposes of PatentProcedure. All restrictions on the availability of the depositedmaterial will be irrevocably removed upon granting of the patent.

DETAILED DESCRIPTION

This description is not intended to be a detailed catalog of all thedifferent ways in which the invention may be implemented, or all thefeatures that may be added to the instant invention. For example,features illustrated with respect to one embodiment may be incorporatedinto other embodiments, and features illustrated with respect to aparticular embodiment may be deleted from that embodiment. Thus, theinvention contemplates that in some embodiments of the invention, anyfeature or combination of features set forth herein can be excluded oromitted. In addition, numerous variations and additions to the variousembodiments suggested herein will be apparent to those skilled in theart in light of the instant disclosure, which do not depart from theinstant invention. Hence, the following descriptions are intended toillustrate some particular embodiments of the invention, and not toexhaustively specify all permutations, combinations and variationsthereof.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. The terminology used in thedescription of the invention herein is for the purpose of describingparticular embodiments only and is not intended to be limiting of theinvention. It is also to be understood that the terminology used hereinis for the purpose of describing particular embodiments only, and is notintended to limit the scope of the present invention.

Definitions

As used herein and in the appended claims, the singular forms “a,”“and,” and “the” include plural reference unless the context clearlydictates otherwise. Thus, for example, reference to “a plant” is areference to one or more plants and includes equivalents thereof knownto those skilled in the art, and so forth. As used herein, the word “or”means any one member of a particular list and also includes anycombination of members of that list (i.e., includes also “and”).

The term “about” is used herein to mean approximately, roughly, around,or in the region of. When the term “about” is used in conjunction with anumerical range, it modifies that range by extending the boundariesabove and below the numerical values set forth. In general, the term“about” is used herein to modify a numerical value above and below thestated value by a variance of 20 percent, preferably 10 percent up ordown (higher or lower). With regard to a temperature the term “about”means±1° C., preferably ±0.5° C. Where the term “about” is used in thecontext of this invention (e.g., in combinations with temperature ormolecular weight values) the exact value (i.e., without “about”) ispreferred.

The term “antibody”, as used herein, broadly refers to anyimmunoglobulin (Ig) molecule comprised of four polypeptide chains, twoheavy (H) chains and two light (L) chains, or any functional fragment,mutant, variant, or derivation thereof, which retains the essentialepitope binding features of an Ig molecule. Such mutant, variant, orderivative antibody formats are known in the art. Non-limitingembodiments of which are discussed below. In a full-length antibody,each heavy chain is comprised of a heavy chain variable region(abbreviated herein as HCVR or VH) and a heavy chain constant region.The heavy chain constant region is comprised of three domains, CH1, CH2and CH3. Each light chain is comprised of a light chain variable region(abbreviated herein as LCVR or VL) and a light chain constant region.The light chain constant region is comprised of one domain, CL. The VHand VL regions can be further subdivided into regions ofhypervariability, termed complementarity determining regions (CDR),interspersed with regions that are more conserved, termed frameworkregions (FR). Each VH and VL is composed of three CDRs and four FRs,arranged from amino-terminus to carboxy-terminus in the following order:FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Immunoglobulin molecules can be ofany type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1,IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

The term “antigen” as used herein means a protein used to trigger animmune response in an organism for the production of an antibody.Antigens according to the present invention include wild-type Cry1Abproteins and hybrid Cry proteins.

The terms “comprises” and/or “comprising,” when used in thisspecification, specify the presence of stated features, integers, steps,operations, elements, and/or components, but do not preclude thepresence or addition of one or more other features, integers, steps,operations, elements, components, and/or groups thereof.

As used herein, the transitional phrase “consisting essentially of” (andgrammatical variants) means that the scope of a claim is to beinterpreted to encompass the specified materials or steps recited in theclaim” and those that do not materially alter the basic and novelcharacteristic(s)” of the claimed invention. Thus, the term “consistingessentially of” when used in a claim of this invention is not intendedto be interpreted to be equivalent to “comprising.”

The term “contacting” refers to a combining action that brings anantibody of the invention into contact with the biological sample andmore particularly to a combining action which brings the antibody intocontact with the Cry1Ab protein or hybrid Cry protein in a manner that abinding interaction will occur between the antibody and the Cry1Abprotein present in the biological sample.

The term “cross-reactivity” refers to the ability of an antibody to binda target protein other than that against which it was raised.

The term “depleted” as used herein means that all or a significantportion of a target protein has been removed from a complex biologicalsample by contacting the biological sample with an antibody that bindsto the target protein. A biological sample that has been “depleted” ofthe target protein has 100% of the target protein removed, or at least95% of the target protein removed, or at least 90%, or at least 85%, orat least 80% of the target protein removed. Thus, for example, abiological sample of the invention comprising Cry1Ab, eCry3.1Ab andCry1A.105 that has been depleted of Cry1Ab, has at least 80% to 100% ofthe Cry1Ab protein removed.

“Detecting antibodies” and “labeled antibodies/labeling antibody” referto antibodies that are capable of being discovered. The detectingantibody may be directly or indirectly (e.g. through another antibody)conjugated to a detectable signal or to a signal-generating moiety. Thesignal can be radioactive (e.g. radioactive iodine, tritium, carbon,sulfur or the like), colorimetric, fluorescent signal and the like.Signal-generating moieties that act on signal-generating substratesinclude, but are not limited to, horseradish peroxidase (HRP) [suitablesubstrates include 3,3′,5,5′-tetramethylbenzidine (TMB); OPD;2,2′-azinobis(3-ethylbenzothiazoline)-6-sulfonic acid diammonium salt];alkaline phosphatase [suitable substrates include p-nitrophenylphosphate disodium salt]; and .beta.-galactosidase [suitable substratesinclude O-nitrophenyl-beta-D-galactopyranoside]. The signal may beamplified by using an Avidin-Biotin conjugation system.

As used herein the term transgenic “event” refers to a recombinant plantproduced by transformation and regeneration of a single plant cell withheterologous DNA, for example, an expression cassette that includes agene of interest. The term “event” refers to the original transformantand/or progeny of the transformant that include the heterologous DNA.The term “event” also refers to progeny produced by a sexual outcrossbetween the transformant and another corn line. Even after repeatedbackcrossing to a recurrent parent, the inserted DNA and the flankingDNA from the transformed parent is present in the progeny of the crossat the same chromosomal location. Normally, transformation of planttissue produces multiple events, each of which represent insertion of aDNA construct into a different location in the genome of a plant cell.Based on the expression of the transgene or other desirablecharacteristics, a particular event is selected. Non-limiting examplesof such transgenic events include “event Bt11” (also Bt11 event or justBt11), “event 5307” (also 5307 event or just 5307), “event MON810” (alsoMON810 event or just MON810) and “event MON89034” (also MON89034 eventor just MON89034. Thus for example, the term “event Bt11”, “Bt11 event”or “Bt11” as used herein means the original Bt11 transformant and/orprogeny of the Bt11 transformant, including any plant derived therefrom.

As used herein the term “hybrid Cry protein” is an engineeredinsecticidal protein that does not exist in nature and at least aportion of which comprises at least a contiguous 27% of a Cry1Abprotein's amino acid sequence. The 27% limitation is calculated bydividing the number of contiguous Cry1Ab amino acids in the hybrid Cryprotein divided by the total number of amino acids in the hybrid Cryprotein. For example, the hybrid Cry protein, eCry3.1Ab (SEQ ID NO:3)has 174 Cry1Ab amino acids (positions 480-653) and a total of 653 aminoacids. Therefore, eCry3A.1Ab has at least a contiguous 27% of a Cry1Abprotein's amino acid sequence. Other examples of a hybrid Cry proteinaccording to the present invention is represented by SEQ ID NO:4 and SEQID NO:5.

The term “isolated” nucleic acid molecule, polynucleotide or toxin is anucleic acid molecule, polynucleotide or toxic protein that no longerexists in its natural environment. An isolated nucleic acid molecule,polynucleotide or toxin of the invention may exist in a purified form ormay exist in a recombinant host such as in a transgenic bacterial cellor a transgenic plant.

The term “monoclonal antibody” refers to an antibody that is derivedfrom a single clone, including any eukaryotic, prokaryotic, or phageclone, and not the method by which it is produced. The term “monoclonalantibody” as used herein is not limited to antibodies produced throughhybridoma technology. Monoclonal antibodies can be prepared using a widevariety of techniques known in the art including the use of hybridoma,recombinant, and phage display technologies, or a combination thereof.For example, it is preferred that monoclonal antibodies of the presentdisclosure be produced using hybridoma techniques including those knownin the art and taught, for example, in Harlow et al., Antibodies: ALaboratory Manual (Cold Spring Harbor Laboratory Press, 2nd ed. 1988);Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas563-681 (Elsevier, N.Y., 1981) (said references incorporated byreference in their entireties). Methods for producing and screening forspecific antibodies using hybridoma technology are routine and wellknown in the art. Briefly, mice can be immunized with the antigen ofinterest. In a preferred embodiment, the antigen is administered with anadjuvant to stimulate the immune response. Such adjuvants includecomplete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides) orISCOM (immunostimulating complexes). Such adjuvants may protect thepolypeptide from rapid dispersal by sequestering it in a local deposit,or they may contain substances that stimulate the host to secretefactors that are chemotactic for macrophages and other components of theimmune system. Preferably, if a polypeptide is being administered, theimmunization schedule will involve two or more administrations of thepolypeptide, spread out over several weeks.

A “plant” is any plant at any stage of development, particularly a seedplant.

A “plant cell” is a structural and physiological unit of a plant,comprising a protoplast and a cell wall. The plant cell may be in theform of an isolated single cell or a cultured cell, or as a part of ahigher organized unit such as, for example, plant tissue, a plant organ,or a whole plant.

“Plant cell culture” means cultures of plant units such as, for example,protoplasts, cell culture cells, cells in plant tissues, pollen, pollentubes, ovules, embryo sacs, zygotes and embryos at various stages ofdevelopment.

“Plant material” refers to leaves, stems, roots, flowers or flowerparts, fruits, pollen, egg cells, zygotes, seeds, cuttings, cell ortissue cultures, or any other part or product of a plant.

A “plant organ” is a distinct and visibly structured and differentiatedpart of a plant such as a root, stem, leaf, flower bud, or embryo.

“Plant tissue” as used herein means a group of plant cells organizedinto a structural and functional unit. Any tissue of a plant in plantaor in culture is included. This term includes, but is not limited to,whole plants, plant organs, plant seeds, tissue culture and any groupsof plant cells organized into structural and/or functional units. Theuse of this term in conjunction with, or in the absence of, any specifictype of plant tissue as listed above or otherwise embraced by thisdefinition is not intended to be exclusive of any other type of planttissue

A “wild-type Cry1Ab protein” means a naturally occurring Cry1Ab proteinor a

Cry1Ab protein with minimal amino acid additions or substitutions to anaturally occurring Cry1Ab amino acid and having the same or similarinsecticidal activity or spectrum as the naturally occurring Cry1Abprotein. A “wild-type Cry1Ab protein” can be either a full-lengthprotein or the truncated toxin portion thereof. For example, withoutlimitation, wild-type Cry1Ab proteins according to the present inventioninclude the Cry1Ab protein of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:6.

The present invention provides immunoassay methods and compositions andkits useful in carrying out the immunoassay methods that allow for thespecific detection of a Cry1Ab protein in complex biological samplescomprising the Cry1Ab protein and at least one hybrid Cry protein havinga contiguous at least 27% of the Cry1Ab protein's amino acid sequence.The current state of the art is such that commercially availableimmunoassays are not useful in differentially detecting a Cry1Ab proteinfrom a hybrid Cry protein engineered using a significant amount of theCry1Ab protein's amino acid sequence when the two proteins are in thesame biological sample because there is high cross-reactivity betweenthe two types of proteins. For example, an antibody raised against awild-type Cry1Ab for use in a Cry1Ab-detecting immunoassay cross reactswith a hybrid Cry protein having a significant number, e.g. at least27%, of its amino acids derived from the wild-type Cry1Ab protein whenthe two proteins are in the same biological sample. Therefore, forexample, the quantitation of the wild-type Cry1Ab in such a complexbiological sample may be confounded by the presence of one or morehybrid Cry proteins. Furthermore, using detection of expressed proteinsfor identity preservation of commercial transgenic plant productscomprising a wild-type Cry1Ab and one or more hybrid Cry proteins of thepresent invention is difficult because of cross-reactivity of antibodiesto both the Cry1Ab proteins and the hybrid Cry proteins in thetransgenic plant products. The methods and compositions disclosed hereinprovide a solution to these problems and rely on pairs of antibodies,e.g. a first antibody and a second antibody, that alone are capable ofbinding both a wild-type Cry1Ab protein and a hybrid Cry protein havingat least a contiguous 27% of the wild-type Cry1Ab protein's amino acidsequence, but surprisingly function together in an immunoassay of theinvention to specifically detect or quantitate the wild-type Cry1Abprotein.

Immunoassays can be carried out in many different formats, examples ofwhich include an enzyme-linked immunosorbent assay (ELISA) and adipstick format, which is also called a lateral flow stick. In ELISA,the protein antigen-antibody reaction takes place on a solid phase,typically in wells on microtiter plates. Antigen and this firstantibody, also called the coating antibody, react and produce a stablecomplex, which can be visualized by addition of a second antibody, alsocalled the detecting antibody, linked to an enzyme. Addition of asubstrate for that enzyme results in a color formation, which can bemeasured photometrically or recognized by eye.

Dipstick formats (lateral flow sticks) typically use paper strips orplastic paddles as support for the capture antibody and this is then thereaction site. The strip/paddle is dipped in vials containing thedifferent biological samples. Each dip is followed by a rinsing step.The final reaction includes a color change in the vial, where thestrip/paddle is placed. Recent development of dipstick format has led tolateral flow techniques where reactants are transported through thechannels of a membrane by capillary forces. One single step is enoughfor performing the assay, and controls for reagent performance areincluded. Antibodies specific to the foreign protein are coupled to acolor reagent and incorporated into the lateral flow strip. When thelateral flow strip is placed in a small amount of a biological sample,for example an extract from plant tissue, that contains foreign protein,binding occurs between the coupled antibody and the protein. A sandwichis formed with some, but not all the antibody that is coupled to thecolor reagent. The membrane contains two capture zones, one captures thebound foreign protein and the other captures color reagent. Thesecapture zones display a reddish color when the sandwich and/ornon-reacted colored reagents are captured in the specific zones on themembrane. The presence of a single line (control line) on the membraneindicates a negative sample and the presence of two lines indicates apositive sample.

In certain embodiments, an antibody as disclosed herein has a detectablelabel. Detectable labels suitable for use in the detection antibodies ofthe present invention include any compound or composition having amoiety that is detectable by spectroscopic, photochemical, biochemical,immunochemical, electrical, optical, or chemical means. Such labelsinclude, for example, an enzyme, oligonucleotide, nanoparticlechemiluminophore, fluorophore, fluorescence quencher, chemiluminescencequencher, or biotin. Thus for example, in an immunoassay employing anoptical signal, the optical signal is measured as an analyteconcentration dependent change in chemiluminescence, fluorescence,phosphorescence, electrochemiluminescence, ultraviolet absorption,visible absorption, infrared absorption, refraction, surface plasmonresonance. In an immunoassay employing an electrical signal, theelectrical signal is measured as an analyte concentration dependentchange in current, resistance, potential, mass to charge ratio, or ioncount. In an immunoassay employing a change-of-state signal, the changeof state signal is measured as an analyte concentration dependent changein size, solubility, mass, or resonance.

Useful labels according to the present disclosure include magnetic beads(e.g., Dynabeads™), fluorescent dyes (e.g., fluorescein, Texas Red,rhodamine, green fluorescent protein) and the like (see, e.g., MolecularProbes, Eugene, Oreg., USA), chemiluminescent compounds such asacridinium (e.g., acridinium-9-carboxamide), phenanthridinium,dioxetanes, luminol and the like, radiolabels (e.g., 3H, 125I, 35S, 14C,or 32P), catalysts such as enzymes (e.g., horse radish peroxidase,alkaline phosphatase, beta-galactosidase and others commonly used in anELISA), and colorimetric labels such as colloidal gold (e.g., goldparticles in the 40-80 nm diameter size range scatter green light withhigh efficiency) or colored glass or plastic (e.g., polystyrene,polypropylene, latex, etc.) beads. Patents teaching the use of suchlabels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350;3,996,345; 4,277,437; 4,275,149; and 4,366,241.

The label can be attached to each antibody prior to, or during, or aftercontact with the biological sample. So-called “direct labels” aredetectable labels that are directly attached to or incorporated into thedetection antibody prior to use in the assay. Direct labels can beattached to or incorporated into the antibody by any of a number ofmeans well known to those of skill in the art. In contrast, so-called“indirect labels” typically bind to each antibody at some point duringthe assay. Often, the indirect label binds to a moiety that is attachedto or incorporated into the detection agent prior to use. Thus, forexample, each antibody can be biotinylated before use in an assay.During the assay, an avidin-conjugated fluorophore can bind thebiotin-bearing detection agent, to provide a label that is easilydetected.

In another example of indirect labeling, polypeptides capable ofspecifically binding immunoglobulin constant regions, such aspolypeptide A or polypeptide G, can also be used as labels for detectionantibodies. These polypeptides are normal constituents of the cell wallsof streptococcal bacteria. They exhibit a strong non-immunogenicreactivity with immunoglobulin constant regions from a variety ofspecies (see, generally Kronval, et al. (1973) J. Immunol., 111:1401-1406, and Akerstrom (1985) J. Immunol., 135: 2589-2542). Suchpolypeptides can thus be labeled and added to the assay mixture, wherethey will bind to each antibody, as well as to the autoantibodies,labeling all and providing a composite signal attributable to analyteand autoantibody present in the sample.

Some labels useful in the present disclosure may require the use of anadditional reagent(s) to produce a detectable signal. In an ELISA, forexample, an enzyme label (e.g., beta-galactosidase) will require theaddition of a substrate (e.g., X-gal) to produce a detectable signal. Inimmunoassays using an acridinium compound as the direct label, a basicsolution and a source of hydrogen peroxide are added.

According to one embodiment, the invention encompasses a compositioncomprising a first antibody and a second antibody that function togetherto specifically detect or quantitate a Cry1Ab protein in an immunoassayof a biological sample comprising the Cry1Ab protein and a hybrid Cryprotein having at least a contiguous 27% of the Cry1Ab protein's aminoacid sequence, wherein the first antibody and the second antibodyindividually are capable of binding to both the wild-type Cry1Ab proteinand the hybrid Cry protein.

In other embodiments of the invention, the immunoassay is anenzyme-linked immunosorbent assay (ELISA), preferably a sandwich ELISA.In still other embodiments, the first antibody is the coating antibodyand the second antibody is the detecting antibody. In still otherembodiments, the first and the second antibodies are monoclonal. In yetother embodiments, the first or coating antibody is the monoclonalantibody 87AB1.1 which is available from Romer Labs, Inc (Union, Mo.).In other embodiments, the second or detecting antibody is the monoclonalantibody H04MAb70 produced by the hybridoma cell line H04MAb70 depositedas ATCC Accession No. PTA-122984. In still other embodiments, thecoating antibody is 87AB1.1 and the detecting antibody is H04MAb70.

In some embodiments of the invention, the Cry1Ab protein that isspecifically detected in an immunoassay of the invention comprises anamino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ IDN:6. In other embodiments, the hybrid Cry protein is eCry3.1Ab,comprising an amino acid sequence set forth in SEQ ID NO:3, Cry1A.105,comprising an amino acid sequence set forth in SEQ ID NO:4, orCry1A.105, comprising an amino acid sequence set forth in SEQ ID NO:5.

In other embodiments of the invention, the biological sample is atransgenic plant sample. In still other embodiments, the transgenicplant is a transgenic corn plant comprising a transgenic event selectedfrom the group consisting of event Bt11, which expresses the Cry1Abprotein of SEQ ID NO:1, event 5307, which expresses the eCry3.1Ab hybridCry protein of SEQ ID NO:3, event MON89034, which expresses theCry1A.105 hybrid Cry protein of SEQ ID NO:5 and event MON810, whichexpresses the Cry1Ab protein of SEQ ID NO:6. In other embodiments, thetransgenic plant comprises event Bt11, event 5307 and event MON89034. Isstill other embodiments, the transgenic plant comprises event MON810 andMON89034.

According to another embodiment, the invention encompasses a pair ofpurified antibodies comprising a first antibody and a second antibodythat function together in an immunoassay to specifically detect orquantitate a Cry1Ab protein in a biological sample comprising the Cry1Abprotein and a hybrid Cry protein having at least a contiguous 27% of theCry1Ab protein's amino acid sequence, wherein the first antibody and thesecond antibody individually are capable of binding to both the Cry1Abprotein and the hybrid Cry protein.

In other embodiments of the invention, the immunoassay is anenzyme-linked immunosorbent assay (ELISA), preferably a sandwich ELISA.In still other embodiments, the first antibody is the coating antibodyand the second antibody is the detecting antibody. In still otherembodiments, the first and the second antibodies are monoclonal. In yetother embodiments, the first or coating antibody is the monoclonalantibody 87AB1.1, which is available from Romer Labs, Inc (Union, Mo.).In other embodiments, the second or detecting antibody is the monoclonalantibody H04MAb70 produced by the hybridoma cell line H04MAb70 depositedas ATCC Accession No. PTA-122984. In still other embodiments, thecoating antibody is 87AB1.1 and the detecting antibody is H04MAb70.

In some embodiments of the invention, the Cry1Ab protein that isspecifically detected in an immunoassay of the invention comprises anamino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ IDN:6. In other embodiments, the hybrid Cry protein is eCry3.1Ab (SEQ IDNO:3), Cry1A.105 (SEQ ID NO:4) or Cry1A.105 (SEQ ID NO:5).

In other embodiments of the invention, the biological sample is atransgenic plant sample. In still other embodiments, the transgenicplant is a transgenic corn plant comprising a transgenic event selectedfrom the group consisting of event Bt11, which expresses the Cry1Abprotein of SEQ ID NO:1, event 5307, which expresses the eCry3.1Ab hybridCry protein of SEQ ID NO:3, event MON89034, which expresses theCry1A.105 hybrid Cry protein of SEQ ID NO:5 and event MON810, whichexpresses the Cry1Ab protein of SEQ ID NO:6. In other embodiments, thetransgenic plant comprises event Bt11, event 5307 and event MON89034. Isstill other embodiments, the transgenic plant comprises event MON810 andMON89034.

According to yet another embodiment, the invention encompasses adiagnostic kit for detecting a Cry1Ab protein in a biological samplewhich comprises the Cry1Ab protein and a hybrid Cry protein having atleast a contiguous 27% of the Cry1Ab protein's amino acid sequence,wherein the kit comprises a first antibody and a second antibody thatfunction together to specifically detect or quantitate the Cry1Abprotein and that individually are capable of binding both the Cry1Abprotein and the hybrid Cry protein.

In other embodiments of the invention, the immunoassay is anenzyme-linked immunosorbent assay (ELISA), preferably a sandwich ELISA.In still other embodiments, the first antibody is the coating antibodyand the second antibody is the detecting antibody. In still otherembodiments, the first and the second antibodies are monoclonal. In yetother embodiments, the first or coating antibody is the monoclonalantibody 87AB1.1, which is available from Romer Labs, Inc (Union, Mo.).In other embodiments, the second or detecting antibody is the monoclonalantibody H04MAb70 produced by the hybridoma cell line H04MAb70 depositedas ATCC Accession No. PTA-122984. In still other embodiments, thecoating antibody is 87AB1.1 and the detecting antibody is H04MAb70.

In some embodiments of the invention, the Cry1Ab protein that isspecifically detected in an immunoassay of the invention comprises anamino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ IDN:6. In other embodiments, the hybrid Cry protein is eCry3.1Ab (SEQ IDNO:3), Cry1A.105 (SEQ ID NO:4) or Cry1A.105 (SEQ ID NO:5).

In other embodiments of the invention, the biological sample is atransgenic plant sample. In still other embodiments, the transgenicplant is a transgenic corn plant comprising a transgenic event selectedfrom the group consisting of event Bt11, which expresses the Cry1Abprotein of SEQ ID NO:1, event 5307, which expresses the eCry3.1Ab hybridCry protein of SEQ ID NO:3, event MON89034, which expresses theCry1A.105 hybrid Cry protein of SEQ ID NO:5 and event MON810, whichexpresses the Cry1Ab protein of SEQ ID NO:6. In yet further embodiments,the biological sample comprises a Cry1Ab protein from event Bt11 and aneCry3.1Ab hybrid Cry protein from event 5307 and optionally a Cry1A.105hybrid Cry protein from event MON89034. In still further embodiments,the biological sample comprises a Cry1Ab protein from event MON810 and aCry1A.105 hybrid Cry protein from event MON89034.

According to another embodiment, the invention encompasses a pair ofpurified antibodies comprising a first antibody and a second antibodythat function together in an immunoassay to specifically detect orquantitate a Cry1Ab protein in a biological sample comprising the Cry1Abprotein and a hybrid Cry protein having at least a contiguous 27% of theCry1Ab protein's amino acid sequence, wherein the first antibody and thesecond antibody individually are capable of binding to both the Cry1Abprotein and the hybrid Cry protein.

In other embodiments of the invention, the immunoassay is anenzyme-linked immunosorbent assay (ELISA), preferably a sandwich ELISA.In still other embodiments, the first antibody is the coating antibodyand the second antibody is the detecting antibody. In still otherembodiments, the first and the second antibodies are monoclonal. In yetother embodiments, the first or coating antibody is the monoclonalantibody 87AB1.1, which is available from Romer Labs, Inc (Union, Mo.).In other embodiments, the second or detecting antibody is the monoclonalantibody H04MAb70 produced by the hybridoma cell line H04MAb70 depositedas ATCC Accession No. PTA-122984. In still other embodiments, thecoating antibody is 87AB1.1 and the detecting antibody is H04MAb70.

In some embodiments of the invention, the Cry1Ab protein that isspecifically detected in an immunoassay of the invention comprises anamino acid sequence represented by SEQ ID NO:1, SEQ ID NO:2 or SEQ IDN:6. In other embodiments, the hybrid Cry protein is eCry3.1Ab (SEQ IDNO:3), Cry1A.105 (SEQ ID NO:4) or Cry1A.105 (SEQ ID NO:5).

In other embodiments of the invention, the biological sample is atransgenic plant sample. In still other embodiments, the transgenicplant is a transgenic corn plant comprising a transgenic event selectedfrom the group consisting of event Bt11, which expresses the Cry1Abprotein of SEQ ID NO:1, event 5307, which expresses the eCry3.1Ab hybridCry protein of SEQ ID NO:3, event MON89034, which expresses theCry1A.105 hybrid Cry protein of SEQ ID NO:5 and event MON810, whichexpresses the Cry1Ab protein of SEQ ID NO:6. . In further embodiments,the biological sample comprises a Cry1Ab protein from event Bt11 and aneCry3.1Ab hybrid Cry protein from event 5307 and optionally a Cry1A.105hybrid Cry protein from event MON89034. In still further embodiments,the biological sample comprises a Cry1Ab protein from event MON810 and aCry1A.105 hybrid Cry protein from event MON89034.

According to another embodiment, the invention encompasses a hybridomacell line, designated H04MAb70, deposited as ATCC Accession No.PTA-122984, and a hybridoma cell line designated MAb58, deposited asATCC Accession No. PTA-122985. In other embodiments, the inventionencompasses a monoclonal antibody designated HO4MAb70 produced by theHO4MAb hybridoma cell line that binds to both a wild-type Cry1Ab proteinand a hybrid Cry protein. In certain other embodiments, the inventionencompasses a monoclonal antibody designated MAb58 produced by thehybridoma cell line MAb58 that binds to a hybrid Cry protein.

According to another embodiment, the invention encompasses immunoassaymethods to specifically detect or quantitate a Cry1Ab protein in abiological sample comprising the Cry1Ab protein and a hybrid Cry proteinhaving at least a contiguous 27% of the Cry1Ab protein's amino acidsequence. Such methods comprise (a) obtaining a biological samplecomprising the Cry1Ab protein and the hybrid Cry protein; and (b)performing an immunoassay on the biological sample, wherein theimmunoassay comprises use of a first antibody and a second antibody thatindividually are capable of binding to the Cry1Ab protein and the hybridCry protein but that function together in the immunoassay tospecifically detect or quantitate the Cry1Ab protein and not the hybridCry protein, resulting in the specific detection or quantitation of theCry1Ab protein.

In some embodiments, the immunoassay is an enzyme-linked immunosorbentassay (ELISA). In other embodiments, the first antibody is a coatingantibody and the second antibody is a detecting antibody. In furtherembodiments, the coating antibody and the detecting antibody aremonoclonal. In still other embodiments, the coating antibody is themonoclonal antibody 87AB1.1 available from Romer Labs, Inc. (Union,Mo.). In yet other embodiments, the detecting antibody is the monoclonalantibody HO4MAb70 produced by the hybridoma cell line deposited as ATCCAccession No. PTA-122984. In other embodiments, the coating antibody is87AB1.1 and the detecting antibody is HO4MAb70.

In some embodiments of the invention, the Cry1Ab protein is selectedfrom the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:6.In other embodiments, the hybrid Cry protein is selected from the groupconsisting of eCry3.1Ab (SEQ ID NO:3), Cry1A.105 (SEQ ID NO:4) and H04(SEQ ID NO:5). In still other embodiments, the Cry1Ab protein comprisesan amino acid of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:6 and thehybrid Cry protein is eCry3.1Ab (SEQ ID NO:3) or Cry1A.105 (SEQ ID NO:4)or H04 (SEQ ID NO:5). In other embodiments, the Cry1Ab protein comprisesthe amino acid sequence of SEQ ID NO:6 and the Cry1A.105 hybrid Cryprotein comprises the amino acid of SEQ ID NO:4.

In some other embodiments of the invention, the biological sample testedin the immunoassay is a transgenic plant sample. In other embodiments,the transgenic plant sample is from a transgenic corn plant. In otherembodiments, the transgenic corn plant comprises a transgenic corn eventselected from the group consisting of event Bt11, event 5307, eventMON89034 and event MON810. In still other embodiments, the transgeniccorn plant comprises event Bt11, event 5307 and event MON89034. In yetother embodiments, the biological sample comprises a Cry1Ab protein fromevent Bt11 and an eCry3.1Ab hybrid Cry protein from event 5307 andoptionally a Cry1A.105 hybrid Cry protein from event MON89034. In otherembodiments, the biological sample comprises a Cry1Ab protein from eventMON810 and a Cry1A.105 hybrid Cry protein from event MON89034.

In another embodiment, the invention encompasses an immunoassay methodfor detecting or quantitating both a Cry1Ab protein and a hybrid Cryprotein having at least a contiguous 27% of a Cry1Ab protein's aminoacid sequence in a biological sample comprising the hybrid Cry proteinand the Cry1Ab protein, the immunoassay method comprising: (a) obtaininga biological sample comprising the hybrid Cry protein and the Cry1Abprotein; (b) contacting the biological sample with a first antibodyunder conditions effective to allow the formation of a Cry1Ab-firstantibody complex but not a hybrid Cry protein-first antibody complex,resulting in a biological sample depleted of the Cry1Ab protein; (c)removing the Cry1Ab-depleted biological sample from contact with thefirst antibody; (d) contacting the Cry1Ab-depleted biological samplewith a second antibody under conditions effective to allow the formationof a hybrid Cry protein-second antibody complex; and (e) detecting orquantitating the hybrid Cry protein in the hybrid Cry protein-secondantibody complex.

In some embodiments, the immunoassay is an enzyme-linked immunosorbentassay, wherein the solid surface is plastic well in a microtiter dish.In some embodiments, the Cry1Ab protein is selected from the groupconsisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:6. In otherembodiments, the hybrid Cry protein is selected from the groupconsisting of eCry3.1Ab (SEQ ID NO:3), Cry1A.105 (SEQ ID NO:4) and H04(SEQ ID NO:5). In still other embodiments, the Cry1Ab protein is SEQ IDNO:1 or SEQ ID NO:2 or SEQ ID NO:6 and the hybrid Cry protein iseCry3.1Ab (SEQ ID NO:3) or Cry1A.105 (SEQ ID NO:4) or H04 (SEQ ID NO:5).In other embodiments, the Cry1Ab protein comprises the amino acidsequence set forth in SEQ ID NO:6 and the Cry1A.105 hybrid Cry proteincomprises the amino acid sequence set forth in SEQ ID NO:4. In stillother embodiments, the Cry1Ab protein is SEQ ID NO:1 and the hybrid Cryprotein is eCry3.1Ab (SEQ ID NO:3) or Cry1A.105 (SEQ ID NO:4).

In other embodiments, the first antibody is 87AB1.1 which is availablefrom Romer Labs, Inc. (Union, Mo.). In still other embodiments, thesecond antibody is the monoclonal antibody MAb58 produced by thehybridoma cell line deposited as ATCC Accession No. PTA-122985. In yetother embodiments of this aspect, the detecting of step (d) is carriedout using a composition comprising a monoclonal antibody capable ofbinding to the Cry1Ab protein and the hybrid Cry protein. In stillfurther embodiments, the monoclonal antibody is HO4MAb70. In yet otherembodiments of this aspect, the detecting step (e) is carried out usinga composition comprising a monoclonal antibody or a polyclonal antibodycapable of binding to the hybrid Cry protein and the Cry1Ab protein. Infurther embodiments, the monoclonal antibody is HO4MAb70 or thepolyclonal antibody is R-PAb available from Romer Labs, Inc. (Union,Mo.).

According to yet another embodiment, the invention encompasses animmunoassay method to detect or quantitate a hybrid Cry protein havingat least a contiguous 27% of a Cry1Ab protein's amino acid sequence in abiological sample comprising the hybrid Cry protein and the Cry1Abprotein. Such methods comprise: (a) obtaining a biological samplecomprising the hybrid Cry protein and the Cry1Ab protein; (b) contactingthe biological sample with a 87AB1.1 antibody under conditions effectiveto allow the formation of a Cry1Ab-87AB1.1 complex but not a hybrid Cryprotein-87AB1.1 complex, resulting in a biological sample depleted ofthe Cry1Ab protein; (c) removing the Cry1Ab-depleted biological samplefrom contact with the 87AB1.1 antibody; (d) contacting theCry1Ab-depleted biological sample with a second antibody underconditions effective to allow the formation of a hybrid Cryprotein-second antibody complex; and (e) detecting or quantitating thehybrid Cry protein in the hybrid Cry protein-second antibody complex.

In some embodiments, the immunoassay is an enzyme-linked immunosorbentassay (ELISA). In some other embodiments of the invention, the Cry1Abprotein is selected from the group consisting of SEQ ID NO:1, SEQ IDNO:2 and SEQ ID NO:6. In other embodiments, the hybrid Cry protein isselected from the group consisting of eCry3.1Ab (SEQ ID NO:3), Cry1A.105(SEQ ID NO:4) and H04 (SEQ ID NO:5). In still other embodiments, theCry1Ab protein is SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:6 and thehybrid Cry protein is eCry3.1Ab (SEQ ID NO:3) or Cry1A.105 (SEQ ID NO:4)or H04 (SEQ ID NO:5). In other embodiments, the Cry1Ab protein comprisesthe amino acid sequence set forth in SEQ ID NO:6 and the Cry1A.105hybrid Cry protein comprises the amino acid sequence set forth in SEQ IDNO:4.

In some other embodiments of the invention, the biological sample testedin the immunoassay is a transgenic plant sample. In other embodiments,the transgenic plant sample is from a transgenic corn plant. In otherembodiments, the transgenic corn plant comprises a transgenic corn eventselected from the group consisting of event Bt11, event 5307, eventMON89034 and event MON810. In still other embodiments, the transgeniccorn plant comprises event Bt11, event 5307 and event MON89034. In yetother embodiments, the biological sample comprises a Cry1Ab protein fromevent Bt11 and an eCry3.1Ab hybrid Cry protein from event 5307 andoptionally a Cry1A.105 hybrid Cry protein from event MON89034. In otherembodiments, the biological sample comprises a Cry1Ab protein from eventMON810 and a Cry1A.105 hybrid Cry protein from event MON89034.

EXAMPLES

The invention will be further described by reference to the followingdetailed examples. These examples are provided for the purposes ofillustration only, and are not intended to be limiting unless otherwisespecified. Standard recombinant DNA and molecular cloning techniquesused here are well known in the art and are described by J. Sambrook, etal., Molecular Cloning: A Laboratory Manual, 3d Ed., Cold Spring Harbor,N.Y.: Cold Spring Harbor Laboratory Press (2001); by T. J. Silhavy, M.L. Berman, and L. W. Enquist, Experiments with Gene Fusions, Cold SpringHarbor Laboratory, Cold Spring Harbor, N.Y. (1984) and by Ausubel, F. M.et al., Current Protocols in Molecular Biology, New York, John Wiley andSons Inc., (1988), Reiter, et al., Methods in Arabidopsis Research,World Scientific Press (1992), and Schultz et al., Plant MolecularBiology Manual, Kluwer Academic Publishers (1998).

Example 1—Screening Antibody Pairs

This example describes antibody embodiments of the invention and theidentification of functional antibody pairs. Antibody pairs were testedfor their ability to specifically detect a Cry1Ab protein (SEQ ID NO:1)when in the presence of an eCry3.1Ab protein (SEQ ID NO:3) or aCry1A.105 protein (SEQ ID NO:4) or both, which are hybrid Cry proteinshaving at least a contiguous 27% of the Cry1Ab protein's amino acidsequence as shown in FIGS. 2 and 3, respectively. Antibodies tested andtheir sources are listed in Table 1.

TABLE 1 Antibodies Tested for Combination Functionality. H04 MAb70Monoclonal antibody raised against a hybrid Cry protein antigencomprising domain I and II of a Cry1Ab, domain III or a Cry1C and aprotoxin tail from a Cry1Ab (See FIG. 1). Hybridoma cell line depositedas ATCC PTA-122984. MAb58 Monoclonal antibody raised against afull-length wild- type Cry1Ab protein antigen. Hybridoma cell linedeposited as ATCC PTA-122985. PAb713 Polyclonal antibody available fromRomer Labs, Inc (Union, MO) raised against a wild-type Cry1Ab proteinantigen. 87AB1.1 Monoclonal antibody available from Romer Labs, Inc.(Union, MO) raised against a wild-type Cry1Ab protein antigen. Cry1Ab/Polyclonal antibody conjugate available from Cry1Ac Con EnviroLogix(Portland, ME) raised against a wild- type Cry1Ab/Cry1Ac proteinantigen.

Antibody pairs are tested in a standard sandwich ELISA. Wells of a96-well plate are coated with a first antibody (coating antibody),typically by incubating over night at approximately 2°-8° C. Plates arethen washed before adding a sample comprising a Cry1Ab protein, aCry1A.105 protein and an eCry3.1Ab protein. Wells are then thoroughlymixed by moving the plate for approximately 20-30 sec, after which theplates are incubated at ambient temperature for approximately 1 to 2hours. Optionally the plate may be shaken on an orbital shaker atapproximately 200 rpm during the incubation period. After incubation,sample liquid is removed from the wells and the wells are washedcompletely 2-3× with a wash buffer. After washing, a second antibody(detection antibody) labelled with a detection enzyme is added to thewells. The plates are incubated at ambient temperature for anotherapproximately 1 to 2 hours. After incubation the plates are washedcompletely with wash buffer. Approximately 100 μl of substrate is thenadded to each well and the plates incubated at ambient temperature forapproximately 15-30 minutes. Plates are inspected for substrate colordevelopment and scored as positive, “+” or negative “−” for each of thethree proteins of interest.

Surprisingly, the results, shown in Table 2, demonstrate that whenindividual antibodies that are capable of binding all three proteins,i.e. Cry1Ab, eCry3.1Ab and Cry1A.105, are used in pairs, the pairsfunction collectively to be selective for either Cry1Ab or a hybrid Cryprotein. This is even more surprising for individual antibodies that areraised against a wild-type Cry1Ab protein like 87AB1.1 and MAb58 or foran antibody raised against a hybrid protein made up of almost 70% ofwild-type Cry1Ab amino acid sequence like H04MAb70 (See FIGS. 1 and 4).Alone such an antibody cannot differentiate between Cry1Ab, Cry1A.105 oreCry3.1Ab. However, in combination with another antibody, the first orthe second antibody is now made selective for just Cry1Ab. For example,these results surprisingly demonstrate that an immunoassay of a complexbiological sample comprising Cry1Ab, Cry1A.105 and eCry3A.1Ab using apair of antibodies, where the first antibody is 87AB1.1, a monoclonalantibody raised against a wild-type Cry1Ab protein that is capable ofbinding both a Cry1Ab protein and an eCry3.1Ab protein, which is ahybrid Cry protein having at least a contiguous 27% of the Cry1Abprotein's amino acid sequence, and the second antibody is H04MAb70, amonoclonal antibody raised against a hybrid Cry protein having at leastone contiguous 39% of a Cry1Ab protein's amino acid sequence and capableof binding Cry1Ab, Cry1A.105 and eCry3.1Ab, specifically detects theCry1Ab protein. Thus when used in combination, the functionality of thefirst antibody and the second antibody is markedly different than eitherof the antibodies alone.

The results also surprisingly demonstrate that an immunoassay of acomplex biological sample comprising Cry1Ab, Cry1A.105 and eCry3.1Abusing a pair of antibodies, where the first antibody is MAb58, amonoclonal antibody raised against a wild-type Cry1Ab protein, and thesecond antibody is H04MAb70, is selective for the Cry1A.105 protein.Thus, when used in combination, the functionality of the first antibody,MAb58, and the second antibody, H04MAb70, is markedly different thaneither antibody alone.

TABLE 2 Results of the Antibody Combination Tests. Detection ProteinDetected in ELISA Coating Antibody Antibody Cry1Ab Cry1A.105 eCry3.1AbHO4 MAb70 PAb713 + + + PAb713 HO4 MAb70 + − + 87Ab1.1 PAb713 + − +PAb713 MAb 87Ab1.1 + + − Mab58 PAb713 − + − Mab58 HO4 MAb70 − + −87Ab1.1 HO4 MAb70 + − − Cry1Ab-Ac Con Cry1Ab-Ac + − + Con PAb713Cry1Ab-Ac + + + Con

Example 2—Quantitative Analysis for Cry1Ab

This example describes a procedure for specific detection andquantification of a

Cry1Ab protein in a complex biological sample, for example a transgenicplant sample, comprising the Cry1Ab protein and two hybrid Cry proteinshaving at least a contiguous 27% of the Cry1Ab protein's amino acidsequence by enzyme linked immunosorbent assay (ELISA).

A 96-well Nunc Maxisorp plate is coated with 100 μl per well of asolution comprising the monoclonal antibody 87AB1.1, available fromRomer Labs, Inc (Union, Mo.). Plates are covered with a 96-well platelid and incubated minimally overnight at approximately 2° C. to 8° C. Ifthe plates are allowed to incubate longer than overnight, cover theplate with an adhesive plate sealer to prevent evaporation andcontamination of the wells. Wash the plates at least three times with 1×phosphate buffered saline with Tween® 20 (PBST) wash buffer (§ 11.2.3)using approximately 300 μl/well. As a blocking step, add approximately200 μl of Superblock® per well. Incubate the plates at room temperaturewhile shaking at approximately 400 rpm for at least 30 minutes. Wash theplates at least three times with 1×PBST wash buffer using approximately300 μl/well.

Dilutions: Sample extracts are diluted in 1× PBST (137 mM sodiumchloride, 2.7 mM potassium chloride, 10 mM sodium phosphate dibasic, 1.8mM potassium phosphate monobasic and 0.05% Tween® 20) with 1% bovineserum albumin (BSA) buffer. At least two dilutions of each sampleextract should be analyzed to obtain multiple concentrations across thequantitative range of the standard curve. Sample extracts should bemixed thoroughly before use. Prepare a minimum volume of the initialdilution so that sufficient volume is available to create subsequentdilutions for accurate duplicate analysis (100 μl each). Increase thevolume of the initial dilution appropriately if samples will be analyzedin triplicate. Mix dilutions by pipetting up and down several times. Forexample, a 1:20 dilution would be made up as follows: 760 μl of 1×PBSTwith 1% BSA buffer+40 μl of extract=800 μl (total volume). Subsequent1:2 dilutions can be made from the first dilution. The minimum dilutionfactor for all matrices is located in Table 1.

Preparation of Standard Curve: Prepare the standard curve containing thefollowing concentrations of Cry1Ab in 1×PBST with 1% BSA buffer: 12.5,6.25, 3.13, 1.56, 0.781, 0.391, 0.195 and 0.098 ng/ml. See Table 3 forexample dilution series. Solutions may be prepared in microtubes tofacilitate efficient loading of ELISA plates with standard curvesolution.

TABLE 3 Cry1Ab Standard Curve Preparation (provides standard solutionsfor one plate; adjust volumes as necessary for additional plates)Dilution of Concentration Previous Volume of PBST + 1% Final Standard ofPrevious Solution Previous BSA Buffer Concentration Final Solution(ng/ml) (1:X) Solution (μl) Volume (μl) (ng/ml) Volume (μl) 82000*    82 10 810 1000 810 1000     80 10 790 12.5 400 12.5   2 400 400 6.25 4006.25  2 400 400 3.13 400 3.13  2 400 400 1.56 400 1.56  2 400 400 0.781400 0.781 2 400 400 0.391 400 0.391 2 400 400 0.195 400 0.195 2 400 4000.098 800

Loading the Plate: Sample extract dilutions should be prepared so thatthe plate can be loaded quickly and efficiently to minimize variation inincubation time between the first and last samples loaded. Place 100 μlof the standards in the wells in triplicate, then place 100 μl ofsamples and PACS into the wells in no less than duplicate. Cover theplate and incubate at room temperature for at least one hour whileshaking at approximately 400 rpm.

Wash the plate at least five times with 1× PBST buffer withapproximately 300 μl/well. Add 100 μl/well of the appropriately dilutedH04Mab 70-HRP antibody. Cover the plate and incubate at room temperaturefor at least one hour while shaking at approximately 400 rpm. Wash theplate at least five times with 1×PBST buffer with approximately 300μl/well. Add 100 μl/well of the TMB substrate solution (1 tablet TMB, 10ml citrate phosphate buffer and 2 μl hydrogen peroxide) using anappropriate multichannel device to each well of the plate(s) andincubate the plate at room temperature, in the dark, while shaking atapproximately 400 rpm until the appropriate color development has beenachieved (approximately 15 minutes). Stop the reaction by adding 50μl/well of 3 M sulfuric acid. Read the absorbance of the wells at awavelength of 450 nm using a SPECTRAmax Pro plate reader. Other platereaders may be used if necessary.

Interpretation of Results: Data are analyzed using SoftMax® Pro softwareor equivalent.

Standard Curve: A 4-parameter logistic algorithm is used to fit thestandard curve. For each standard curve dilution, the coefficient ofvariation (CV) of the optical density (OD) values must be ≤20%. Aminimum of two replicates is required for analysis; one of thetriplicate OD values may be omitted as needed to yield an acceptable CVvalue. For documentation purposes, this is indicated on the dataprintout by both drawing a single line through the omitted data pointand writing the corrected mean in the “mean” column or by masking thewell in the software program used for analysis. If the CV of the ODvalues of duplicate standards is >20%, then the ELISA must be repeated.The mean back calculated concentration (MBCC) value must be within70%-120% of the nominal concentration for each standard point within thequantitative range of the assay. One of the triplicate OD values may beomitted as needed to yield an acceptable criterion, however a minimum oftwo replicates is required for analysis; See § 9.2.2 for documentationguidelines. The quantitative range of the Cry1Ab standard curve is 0.195ng/ml to 12.5 ng/ml. The coefficient of determination (R²) must be≥0.990.

Positive Assay Control Sample: For each PACS dilution, the CV betweenreplicate concentrations must be ≤20%. To be a valid PACS dilution, aminimum of two replicates is required for analysis. If assayed intriplicate, one of the triplicate concentrations may be omitted asneeded to yield an acceptable CV value. To calculate the mean PACSconcentration, multiply the measured concentration (ng/ml) by thecorresponding dilution factor to determine the calculated concentrationfor each dilution in μg/ml. Average all calculated concentrations thatfall within the accurate range of the assay to determine the overallCry1Ab PACS concentration in μg/ml. The CV of the calculatedconcentration among PACS dilutions must be ≤20%. If the CV of thecalculated concentration among PACS dilutions is >20%, and/or the meanPACS concentration is outside the specification range, the ELISA platedata is invalidated and all samples on that plate will be reanalyzed inanother ELISA session.

Test Samples: For each sample dilution, the CV between replicateconcentrations must be ≤20%. To be a valid sample dilution, a minimum oftwo replicates is required for analysis. If assayed in triplicate, oneof the triplicate concentrations may be omitted as needed to yield anacceptable CV value. The mean measured concentration obtained by ELISAfor each sample dilution must lie within the quantitative range of theELISA (Table 2). To calculate the sample concentration, multiply eachmeasured sample protein concentration that is within the quantitativerange of the ELISA by the corresponding dilution factor. Average theresults from at least two sample dilutions to determine the overallsample concentration, unless the sample dilution at the minimum dilutionfactor for a given matrix is the only result within the quantitativerange. The CV of the calculated concentration among sample dilutionsmust be ≤20%. If the CV among sample dilutions is >20% and more than twodilutions are used to calculate the concentration, one outlying dilutionmay be omitted and the mean concentration recalculated from theremaining dilutions.

Results: Samples of leaf, kernel and root tissue from a triple stack(three events) transgenic corn plant comprising the transgenic cornevents Bt11 expressing Cry1Ab, 5307 expressing eCry3.1Ab and MON89034expressing Cry1A.105 were tested using the immunoassay described aboveto quantitate specifically the Cry1Ab protein concentration in thesamples. Four different samples for each tissue were prepared and 3replicates from each sample were assayed. The concentration of Cry1Abprotein in transgenic corn comprising the Bt11 event alone has beenreported to range from approximately 12-154 μg/g dry weight (DW) inleaves and approximately 9-22 μg/gDW in roots (September 2010. USEnvironmental Protection Agency Biopesticides Registration ActionDocument. Cry1Ab and Cry1F Bacillus thuringiensis (Bt) CornPlant-Incorporated Protectants). Results of the immunoassay of a stackedproduct, shown in Table 4, demonstrate that the concentration of Cry1Abin the stacked product is comparable to the Cry1Ab concentration in Bt11alone, indicating that the immunoassay can specifically detect andquantitate Cry1Ab in the presence of one or more hybrid Cry proteinshaving at a contiguous 27% of the Cry1Ab protein's amino acid sequence.

TABLE 4 Quantitation of Cry1Ab in a Sample Comprising Cry1Ab, eCry3.1Aband Cry1A.105. Mean Cry1Ab Standard Concentration Deviation Range Sample(μg/gDW) (SD) (−2 to +2 SD) Leaf 70.79 5.34 60.12-81.47 Root 18.69 1.8514.99-22.38 Kernel 3.98 0.49 3.00-4.97

Example 3—Quantitation of a Hybrid Cry Protein or Both a Cry1Ab Proteinand Hybrid Cry Protein in Same Immunoassay

Based on the discovery that certain antibody pairs have markedlydifferent function than either antibody when used alone, a serialimmunoassay was developed that allows for detection or quantitation ofboth a wild-type Cry1Ab and a hybrid Cry protein having a contiguous 27%of the Cry1Ab protein's amino acid sequence in the same immunoassay.Briefly the method comprises coating a first 96-well microtiter platewith the 87AB1.1 monoclonal antibody, which when used in a pair ofantibodies selectively detects a wild-type Cry1Ab protein in a mixtureof Cry1Ab and a hybrid Cry protein and a second 96-well microtiter platewith a MAb58 antibody. Contacting a biological sample from a transgenicplant comprising a Cry1Ab protein from event Bt11, a hybrid Cry protein,eCry3.1Ab, from event 5307 and a hybrid Cry protein, Cry1A.105, fromevent MON89034 with the 87AB1.1 antibody under conditions effective toallow the formation of a Cry1Ab-87AB1.1 complex but not a hybrid Cryprotein-87AB1.1 complex as described above in Example 2. This results ina biological sample in the microtiter wells that is depleted of theCry1Ab protein. Next remove the Cry1Ab-depleted biological sample fromthe first microtiter dish and transfer to the second microtiter dish,contacting the Cry1Ab-depleted biological sample with the MAb58 antibodyunder conditions effective to allow the formation of a Cry1A.105-MAb58complex. Next add the appropriate dilution of a solution comprising aH04MAb70-HRP labelled antibody or a PAb713-HRP labelled antibody.Incubated under conditions effective to allow the formation of aCry1A.105-H04MAb70 or Cry1A.105-PAb713 complex. Then add a substrate todetect or quantitate the Cry1A.105 protein by comparing to a Cry1A.105standard curve.

Optionally, the Cry1Ab protein on the first microtiter plate can also bedetected or quantitated in the same immunoassay by following theprocedure described in Example 2.

It should be understood that the examples and embodiments describedherein are for illustrative purposes only and that various modificationsor changes in light thereof will be suggested to persons skilled in theart and are to be included within the spirit and purview of thisapplication and the scope of the appended claims.

All publications and patent applications mentioned in this specificationare indicative of the level of skill of those skilled in the art thatthis invention pertains. All publications and patent applications areherein incorporated by reference to the same extent as if eachindividual publication or patent application was specifically andindividually indicated to be incorporated by reference.

What is claimed is:
 1. A composition comprising a first monoclonal MAb58antibody produced by a hybridoma cell line deposited as ATCC AccessionNo. PTA-122985 and a second antibody that is a) a monoclonal antibodyH04MAb70 produced by a hybridoma cell line deposited as ATCC AccessionNo. PTA-122984; orb) a polyclonal antibody PAb713, that functiontogether to specifically detect or quantitate a Cry1A.105 proteincomprising SEQ ID NO:4 in an immunoassay of a biological samplecomprising the Cry1A.105 protein and a Cry1Ab protein comprising SEQ IDNO:1, wherein the first antibody and the second antibody individuallyare capable of binding to both the Cry1Ab protein and the Cry1A.105protein but that function together in the immunoassay to specificallydetect or quantitate the Cry1A.105 protein and not the Cry1Ab protein.2. The composition of claim 1, wherein the immunoassay is anenzyme-linked immunosorbent assay (ELISA).
 3. The composition of claim2, wherein the first antibody is a coating antibody and the secondantibody is a detecting antibody.
 4. The composition of claim 3, whereinthe coating antibody is MAb58 and the detecting antibody is PAb713. 5.The composition of claim 3, wherein the coating antibody is MAb58 andthe detecting antibody is H04MAb70.
 6. The composition of claim 1,wherein the biological sample is a transgenic plant sample.
 7. Thecomposition of claim 6, wherein the transgenic plant is a transgeniccorn plant.
 8. The composition of claim 7, wherein the transgenic cornplant comprises event MON89034.
 9. The composition of claim 8, whereinthe Cry1A.105 protein is from event MON89034 and the Cry1Ab protein isfrom Bt11.
 10. The composition of claim 9, wherein the biological samplefurther comprises an eCry3A.1Ab protein from event
 5307. 11. Amonoclonal antibody produced by a hybridoma deposited as ATCC AccessionNo. PTA-122985.
 12. The monoclonal antibody of 11 that is an MAb58antibody.
 13. A method for specifically detecting or quantitating aCry1A.105 protein comprising SEQ ID NO:4 in a biological sample from atransgenic plant comprising the Cry1A.105 protein and a Cry1Ab proteincomprising SEQ ID NO:1, the method comprising (a) obtaining thebiological sample; (b) performing an immunoassay on the biologicalsample, wherein the immunoassay comprises the composition of claim 1,resulting in the specific detection or quantitation of the Cry1A.105protein.
 14. The method of claim 13, wherein the transgenic plant is atransgenic corn plant that comprises event MON89034.
 15. The method ofclaim 14, wherein the transgenic plant further comprises event Bt11 orevent
 5307. 16. An immunoassay method to detect or quantitate aCry1A.105 protein comprising SEQ ID NO:4 and a Cry1Ab protein comprisingSEQ ID NO:1 in a biological sample from a transgenic corn plantcomprising the Cry1Ab protein and the Cry1A.105 protein, the methodcomprising: (a) coating a first solid surface with a first antibody thatis MAb58 produced by a hybridoma cell line deposited as ATCC AccessionNo. PTA-122985 that binds the Cry1A.105 protein but does not bind theCry1Ab protein and coating a second solid surface with a second antibodythat is 87AB1.1 that binds the Cry1Ab protein; (b) contacting thebiological sample with the MAb58 antibody under conditions effective toallow the formation of a Cry1A.105-MAb58 antibody complex but does notallow the formation of a Cry1Ab-MAb58 antibody complex, resulting in aCry1A.105-depleted biological sample; (c) removing theCry1A.105-depleted biological sample and contacting theCry1A.105-depleted biological sample with the 87AB1.1 antibody underconditions effective to allow the formation of a Cry1Ab protein-87AB1.1antibody complex; (d) detecting or quantitating the Cry1A.105 proteincomplex on the first solid surface; and (e) detecting or quantitatingthe Cry1Ab protein on the second solid surface.
 17. The method of claim16, wherein the detecting of steps (d) or (e) is carried out using acomposition comprising an antibody capable of binding to the Cry1A.105protein and the Cry1Ab protein.
 18. The method of claim 17, wherein theantibody is a monoclonal antibody that is H04MAb70 produced by ahybridoma cell line deposited as ATCC Accession No. PTA-122984.
 19. Themethod of claim 17, wherein the antibody is a polyclonal antibody thatis PAb713.